<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39452475</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-9721</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases (Basel, Switzerland)</Title><ISOAbbreviation>Diseases</ISOAbbreviation></Journal><ArticleTitle>Cytokine Storms and Anaphylaxis Following COVID-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">231</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diseases12100231</ELocationID><Abstract><AbstractText>Acute adverse reactions to COVID-19 mRNA vaccines are a major concern, as autopsy reports indicate that deaths most commonly occur on the same day of or one day following vaccination. These acute reactions may be due to cytokine storms triggered by lipid nanoparticles (LNPs) and anaphylaxis induced by polyethene glycol (PEG), both of which are vital constituents of the mRNA-LNP vaccines. Kounis syndrome, in which anaphylaxis triggers acute coronary syndrome (ACS), may also be responsible for these cardiovascular events. Furthermore, COVID-19 mRNA-LNP vaccines encompass adjuvants, such as LNPs, which trigger inflammatory cytokines, including interleukin (IL)-1β and IL-6. These vaccines also produce spike proteins which facilitate the release of inflammatory cytokines. Apart from this, histamine released from mast cells during allergic reactions plays a critical role in IL-6 secretion, which intensifies inflammatory responses. In light of these events, early reduction of IL-1β and IL-6 is imperative for managing post-vaccine cytokine storms, ACS, and myocarditis. Corticosteroids can restrict inflammatory cytokines and mitigate allergic responses, while colchicine, known for its IL-1β-reducing capabilities, could also prove effective. The anti-IL-6 antibody tocilizumab also displays promising treatment of cytokine release syndrome. Aside from its significance for treating anaphylaxis, epinephrine can induce coronary artery spasms and myocardial ischemia in Kounis syndrome, making accurate diagnosis essential. The upcoming self-amplifying COVID-19 mRNA-LNP vaccines also contain LNPs. Given that these vaccines can cause a cytokine storm and allergic reactions post vaccination, it is crucial to consider corticosteroids and measure IL-6 levels for effective management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Awaya</LastName><ForeName>Toru</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7154-3606</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi Meguro-ku, Tokyo 153-8515, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Hidehiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi Meguro-ku, Tokyo 153-8515, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moroi</LastName><ForeName>Masao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2324-8407</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi Meguro-ku, Tokyo 153-8515, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Misato Central General Hospital, Saitama 341-8526, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diseases</MedlineTA><NlmUniqueID>101636232</NlmUniqueID><ISSNLinking>2079-9721</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kounis syndrome</Keyword><Keyword MajorTopicYN="N">adverse reaction</Keyword><Keyword MajorTopicYN="N">anaphylaxis</Keyword><Keyword MajorTopicYN="N">corticosteroid</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">inflammatory cytokine</Keyword><Keyword MajorTopicYN="N">interleukin 6</Keyword><Keyword MajorTopicYN="N">lipid nanoparticles</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39452475</ArticleId><ArticleId IdType="pmc">PMC11507195</ArticleId><ArticleId IdType="doi">10.3390/diseases12100231</ArticleId><ArticleId IdType="pii">diseases12100231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosenblum H.G., Gee J., Liu R., Marquez P.L., Zhang B., Strid P., Abara W.E., McNeil M.M., Myers T.R., Hause A.M., et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: An observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect. Dis. 2022;22:802–812. doi: 10.1016/S1473-3099(22)00054-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00054-8</ArticleId><ArticleId IdType="pmc">PMC8901181</ArticleId><ArticleId IdType="pubmed">35271805</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata K., Nakao N., Ishiuchi N., Fukui T., Katsuya N., Fukumoto W., Oka H., Yoshikawa N., Nagao T., Namera A., et al. Four cases of cytokine storm after COVID-19 vaccination: Case report. Front. Immunol. 2022;13:967226. doi: 10.3389/fimmu.2022.967226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.967226</ArticleId><ArticleId IdType="pmc">PMC9420842</ArticleId><ArticleId IdType="pubmed">36045681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nushida H., Ito A., Kurata H., Umemoto H., Tokunaga I., Iseki H., Nishimura A. A case of fatal multi-organ inflammation following COVID-19 vaccination. Leg. Med. 2023;63:102244. doi: 10.1016/j.legalmed.2023.102244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.legalmed.2023.102244</ArticleId><ArticleId IdType="pmc">PMC10027302</ArticleId><ArticleId IdType="pubmed">36990036</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglin M.E., Etuk A., Shah C., Ilonze O.J. Fulminant Myocarditis and Cardiogenic Shock Following COVID-19 Infection Versus COVID-19 Vaccination: A Systematic Literature Review. J. Clin. Med. 2023;12:1849. doi: 10.3390/jcm12051849.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12051849</ArticleId><ArticleId IdType="pmc">PMC10003085</ArticleId><ArticleId IdType="pubmed">36902636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Choi J.H., Jang J.Y., So O., Cho E., Choi H., Hong K.S., Park K.T. A Case Report for Myopericarditis after BNT162b2 COVID-19 mRNA Vaccination in a Korean Young Male. J. Korean Med. Sci. 2021;36:e277. doi: 10.3346/jkms.2021.36.e277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e277</ArticleId><ArticleId IdType="pmc">PMC8506415</ArticleId><ArticleId IdType="pubmed">34636504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., Qin Z., Jacobsen S., Bouteau A., Estanbouli H., Igyarto B.Z. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24:103479. doi: 10.1016/j.isci.2021.103479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103479</ArticleId><ArticleId IdType="pmc">PMC8604799</ArticleId><ArticleId IdType="pubmed">34841223</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi C., Terpos E., Rosati M., Angel M., Bear J., Stellas D., Karaliota S., Apostolakou F., Bagratuni T., Patseas D., et al. Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36:109504. doi: 10.1016/j.celrep.2021.109504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109504</ArticleId><ArticleId IdType="pmc">PMC8299183</ArticleId><ArticleId IdType="pubmed">34352226</ArticleId></ArticleIdList></Reference><Reference><Citation>Theobald S.J., Simonis A., Georgomanolis T., Kreer C., Zehner M., Eisfeld H.S., Albert M.C., Chhen J., Motameny S., Erger F., et al. Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Mol. Med. 2021;13:e14150. doi: 10.15252/emmm.202114150.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202114150</ArticleId><ArticleId IdType="pmc">PMC8350892</ArticleId><ArticleId IdType="pubmed">34133077</ArticleId></ArticleIdList></Reference><Reference><Citation>Allam C., Kounis N.G., Chlawit R., Saouma M., Badaoui G. Kounis syndrome following COVID-19 vaccination. Bayl. Univ. Med. Cent. Proc. 2022;35:369–370. doi: 10.1080/08998280.2022.2034226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2022.2034226</ArticleId><ArticleId IdType="pmc">PMC9037488</ArticleId><ArticleId IdType="pubmed">35518825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K., Imai Y., Penninger J.M. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ. J. 2013;77:301–308. doi: 10.1253/circj.CJ-12-1544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-12-1544</ArticleId><ArticleId IdType="pubmed">23328447</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi J., Suda A., Nishimiya K., Godo S., Yasuda S., Shimokawa H. Pathophysiology and Diagnosis of Coronary Functional Abnormalities. Eur. Cardiol. 2021;16:e30. doi: 10.15420/ecr.2021.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/ecr.2021.23</ArticleId><ArticleId IdType="pmc">PMC8478147</ArticleId><ArticleId IdType="pubmed">34603510</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita S., Takagi T., Inaba H., Furukawa Y., Kishimoto S., Uraki S., Shimo N., Takeshima K., Uraki S., Doi K., et al. Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: A twelve-month follow-up study. Front. Endocrinol. 2023;14:1058007. doi: 10.3389/fendo.2023.1058007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1058007</ArticleId><ArticleId IdType="pmc">PMC9911871</ArticleId><ArticleId IdType="pubmed">36777341</ArticleId></ArticleIdList></Reference><Reference><Citation>Irrgang P., Gerling J., Kocher K., Lapuente D., Steininger P., Habenicht K., Wytopil M., Beileke S., Schäfer S., Zhong J., et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2023;8:eade2798. doi: 10.1126/sciimmunol.ade2798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.ade2798</ArticleId><ArticleId IdType="pmc">PMC9847566</ArticleId><ArticleId IdType="pubmed">36548397</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Casillas A., Cowley D., Raszek M., Uversky V.N., Redwan E.M. Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer? Int. J. Biol. Macromol. 2024;267:131427. doi: 10.1016/j.ijbiomac.2024.131427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.131427</ArticleId><ArticleId IdType="pubmed">38583833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonez C., Bessodes M., Scherman D., Vandenbranden M., Escriou V., Ruysschaert J.M. Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways. Nanomedicine. 2014;10:775–782. doi: 10.1016/j.nano.2013.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2013.12.003</ArticleId><ArticleId IdType="pubmed">24361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullis P.R., Hope M.J. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 2017;25:1467–1475. doi: 10.1016/j.ymthe.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.03.013</ArticleId><ArticleId IdType="pmc">PMC5498813</ArticleId><ArticleId IdType="pubmed">28412170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenchov R., Bird R., Curtze A.E., Zhou Q. Lipid Nanoparticles horizontal line From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15:16982–17015. doi: 10.1021/acsnano.1c04996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c04996</ArticleId><ArticleId IdType="pubmed">34181394</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh M.G., Tombacz I., Bettini E., Lederer K., Sittplangkoon C., Wilmore J.R., Gaudette B.T., Soliman O.Y., Pine M., Hicks P., et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877–2892.e7. doi: 10.1016/j.immuni.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Lee A., Grigoryan L., Arunachalam P.S., Scott M.K.D., Trisal M., Wimmers F., Sanyal M., Weidenbacher P.A., Feng Y., et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 2022;23:543–555. doi: 10.1038/s41590-022-01163-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01163-9</ArticleId><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobiyama K., Ishii K.J. Making innate sense of mRNA vaccine adjuvanticity. Nat. Immunol. 2022;23:474–476. doi: 10.1038/s41590-022-01168-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01168-4</ArticleId><ArticleId IdType="pubmed">35354958</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhr O.B., Coelho T., Buades J., Pouget J., Conceicao I., Berk J., Schmidt H., Waddington-Cruz M., Campistol J.M., Bettencourt B.R., et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study. Orphanet J. Rare Dis. 2015;10:109. doi: 10.1186/s13023-015-0326-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-015-0326-6</ArticleId><ArticleId IdType="pmc">PMC4559363</ArticleId><ArticleId IdType="pubmed">26338094</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams D., Gonzalez-Duarte A., O’Riordan W.D., Yang C.C., Ueda M., Kristen A.V., Tournev I., Schmidt H.H., Coelho T., Berk J.L., et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N. Engl. J. Med. 2018;379:11–21. doi: 10.1056/NEJMoa1716153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716153</ArticleId><ArticleId IdType="pubmed">29972753</ArticleId></ArticleIdList></Reference><Reference><Citation>Staedtke V., Bai R.Y., Kim K., Darvas M., Davila M.L., Riggins G.J., Rothman P.B., Papadopoulos N., Kinzler K.W., Vogelstein B., et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564:273–277. doi: 10.1038/s41586-018-0774-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0774-y</ArticleId><ArticleId IdType="pmc">PMC6512810</ArticleId><ArticleId IdType="pubmed">30542164</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu S.S., Tummala S., Kebriaei P., Wierda W., Gutierrez C., Locke F.L., Komanduri K.V., Lin Y., Jain N., Daver N., et al. Chimeric antigen receptor T-cell therapy—Assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2018;15:47–62. doi: 10.1038/nrclinonc.2017.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2017.148</ArticleId><ArticleId IdType="pmc">PMC6733403</ArticleId><ArticleId IdType="pubmed">28925994</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay S.H., Toh M.M.X., Thian Y.L., Vellayappan B.A., Fairhurst A.M., Chan Y.H., Aminkeng F., Bharwani L.D., Huang Y., Mak A., et al. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. Front. Immunol. 2022;13:807050. doi: 10.3389/fimmu.2022.807050.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.807050</ArticleId><ArticleId IdType="pmc">PMC8831742</ArticleId><ArticleId IdType="pubmed">35154124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D.W., Santomasso B.D., Locke F.L., Ghobadi A., Turtle C.J., Brudno J.N., Maus M.V., Park J.H., Mead E., Pavletic S., et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol. Blood Marrow Transpl. 2019;25:625–638. doi: 10.1016/j.bbmt.2018.12.758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2018.12.758</ArticleId><ArticleId IdType="pubmed">30592986</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J., Li J., Lei Y., Chen Z., Wu L., Lin C. Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022. Heliyon. 2024;10:e30955. doi: 10.1016/j.heliyon.2024.e30955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e30955</ArticleId><ArticleId IdType="pmc">PMC11107250</ArticleId><ArticleId IdType="pubmed">38774317</ArticleId></ArticleIdList></Reference><Reference><Citation>Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A., Przepiorka D., Farrell A.T., Pazdur R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23:943–947. doi: 10.1634/theoncologist.2018-0028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2018-0028</ArticleId><ArticleId IdType="pmc">PMC6156173</ArticleId><ArticleId IdType="pubmed">29622697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuckermann J.P., Kleiman A., Moriggl R., Spanbroek R., Neumann A., Illing A., Clausen B.E., Stride B., Forster I., Habenicht A.J., et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Investig. 2007;117:1381–1390. doi: 10.1172/JCI28034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28034</ArticleId><ArticleId IdType="pmc">PMC1849982</ArticleId><ArticleId IdType="pubmed">17446934</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcock J., Masters A. Cytokine storms, evolution and COVID-19. Evol. Med. Public Health. 2021;9:83–92. doi: 10.1093/emph/eoab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emph/eoab005</ArticleId><ArticleId IdType="pmc">PMC7928963</ArticleId><ArticleId IdType="pubmed">34552755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Topete D., Cidlowski J.A. Immunopharmacology and Inflammation. Springer; Cham, Switzerland: 2018. Glucocorticoids: Molecular Mechanisms of Action; pp. 249–266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-77658-3_11</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S., Tanaka T., Inoue H., Ono C., Hashimoto S., Kioi Y., Matsumoto H., Matsuura H., Matsubara T., Shimizu K., et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc. Natl. Acad. Sci. USA. 2020;117:22351–22356. doi: 10.1073/pnas.2010229117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010229117</ArticleId><ArticleId IdType="pmc">PMC7486751</ArticleId><ArticleId IdType="pubmed">32826331</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T., Minaga K., Hara A., Yoshikawa T., Kamata K., Kudo M. Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 Vaccination. Front. Immunol. 2022;13:859926. doi: 10.3389/fimmu.2022.859926.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.859926</ArticleId><ArticleId IdType="pmc">PMC9198350</ArticleId><ArticleId IdType="pubmed">35720324</ArticleId></ArticleIdList></Reference><Reference><Citation>Alunno A., Carubbi F., Ferri C. Colchicine and cardiovascular prevention. Eur. J. Intern. Med. 2024;121:30–34. doi: 10.1016/j.ejim.2023.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2023.12.028</ArticleId><ArticleId IdType="pubmed">38171936</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen M.B., Gregersen I., Sandanger O., Yang K., Sokolova M., Halvorsen B.E., Gullestad L., Broch K., Aukrust P., Louwe M.C. Targeting the Inflammasome in Cardiovascular Disease. JACC Basic Transl. Sci. 2022;7:84–98. doi: 10.1016/j.jacbts.2021.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2021.08.006</ArticleId><ArticleId IdType="pmc">PMC8807732</ArticleId><ArticleId IdType="pubmed">35128212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.Y., Jeong Y.H., Yun K.H., Cho J.Y., Gorog D.A., Angiolillo D.J., Kim J.W., Jang Y. P2Y(12) Inhibitor Monotherapy Combined with Colchicine Following PCI in ACS Patients: The MACT Pilot Study. JACC Cardiovasc. Interv. 2023;16:1845–1855. doi: 10.1016/j.jcin.2023.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2023.05.035</ArticleId><ArticleId IdType="pubmed">37587591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav K.P. Is Colchicine the New “Aspirin”? Indian J. Clin. Cardiol. 2024;5:42–49. doi: 10.1177/26324636231219373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/26324636231219373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto J., Awaya T., Nakagawa T., Tamura A., Hiroi Y. Myocarditis with ventricular tachycardia following bivalent COVID-19 mRNA vaccination. CJC Open. 2023;5:654–657. doi: 10.1016/j.cjco.2023.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjco.2023.05.006</ArticleId><ArticleId IdType="pmc">PMC10193770</ArticleId><ArticleId IdType="pubmed">37362315</ArticleId></ArticleIdList></Reference><Reference><Citation>Flego D., Cesaroni S., Romiti G.F., Corica B., Marrapodi R., Scafa N., Maiorca F., Lombardi L., Pallucci D., Pulcinelli F., et al. Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID-19 vaccine. J. Thromb. Haemost. 2022;20:961–974. doi: 10.1111/jth.15648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15648</ArticleId><ArticleId IdType="pmc">PMC9302646</ArticleId><ArticleId IdType="pubmed">35032087</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardif J.C., Kouz S., Waters D.D., Bertrand O.F., Diaz R., Maggioni A.P., Pinto F.J., Ibrahim R., Gamra H., Kiwan G.S., et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N. Engl. J. Med. 2019;381:2497–2505. doi: 10.1056/NEJMoa1912388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912388</ArticleId><ArticleId IdType="pubmed">31733140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoekstra S.P., Bishop N.C., Faulkner S.H., Bailey S.J., Leicht C.A. Acute and chronic effects of hot water immersion on inflammation and metabolism in sedentary, overweight adults. J. Appl. Physiol. 2018;125:2008–2018. doi: 10.1152/japplphysiol.00407.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00407.2018</ArticleId><ArticleId IdType="pubmed">30335579</ArticleId></ArticleIdList></Reference><Reference><Citation>Awaya T., Moroi M., Enomoto Y., Kunimasa T., Nakamura M. What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions. Vaccines. 2022;10:866. doi: 10.3390/vaccines10060866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060866</ArticleId><ArticleId IdType="pmc">PMC9228524</ArticleId><ArticleId IdType="pubmed">35746474</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakroo Abkenar I., Rahmani-Nia F., Lombardi G. The Effects of Acute and Chronic Aerobic Activity on the Signaling Pathway of the Inflammasome NLRP3 Complex in Young Men. Medicina. 2019;55:105. doi: 10.3390/medicina55040105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina55040105</ArticleId><ArticleId IdType="pmc">PMC6524053</ArticleId><ArticleId IdType="pubmed">30991661</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.R., Abshire K.M., Farokhnia M., Akhlaghi F., Leggio L. Effect of oral alcohol administration on plasma cytokine concentrations in heavy drinking individuals. Drug Alcohol. Depend. 2021;225:108771. doi: 10.1016/j.drugalcdep.2021.108771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2021.108771</ArticleId><ArticleId IdType="pubmed">34052691</ArticleId></ArticleIdList></Reference><Reference><Citation>Amioka N., Nakamura K., Kimura T., Ohta-Ogo K., Tanaka T., Toji T., Akagi S., Nakagawa K., Toh N., Yoshida M., et al. Pathological and clinical effects of interleukin-6 on human myocarditis. J. Cardiol. 2021;78:157–165. doi: 10.1016/j.jjcc.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2021.03.003</ArticleId><ArticleId IdType="pubmed">33814251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.W., Yap S.F., Amin-Nordin S., Ngeow Y.F. Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series. Vaccines. 2024;12:575. doi: 10.3390/vaccines12060575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12060575</ArticleId><ArticleId IdType="pmc">PMC11209191</ArticleId><ArticleId IdType="pubmed">38932303</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson U., Kurrer M.O., Schmitz N., Marsch S.C., Fontana A., Eugster H.P., Kopf M. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation. 2003;107:320–325. doi: 10.1161/01.CIR.0000043802.38699.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000043802.38699.66</ArticleId><ArticleId IdType="pubmed">12538435</ArticleId></ArticleIdList></Reference><Reference><Citation>Tall A.R., Bornfeldt K.E. Inflammasomes and Atherosclerosis: A Mixed Picture. Circ. Res. 2023;132:1505–1520. doi: 10.1161/CIRCRESAHA.123.321637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.123.321637</ArticleId><ArticleId IdType="pmc">PMC10213995</ArticleId><ArticleId IdType="pubmed">37228237</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi T., Awaya T., Yoshioka K., Kitano S., Hayama H., Amemiya K., Enomoto Y., Yazaki Y., Moroi M., Nakamura M. Myocarditis after COVID-19 mRNA vaccines. QJM. 2021;114:741–743. doi: 10.1093/qjmed/hcab244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab244</ArticleId><ArticleId IdType="pubmed">34546329</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster M.E., Shay D.K., Su J.R., Gee J., Creech C.B., Broder K.R., Edwards K., Soslow J.H., Dendy J.M., Schlaudecker E., et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327:331–340. doi: 10.1001/jama.2021.24110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Noe A., Dang T.D., Axelrad C., Burrell E., Germano S., Elia S., Burgner D., Perrett K.P., Curtis N., Messina N.L. BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists. Front. Immunol. 2023;14:1242380. doi: 10.3389/fimmu.2023.1242380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1242380</ArticleId><ArticleId IdType="pmc">PMC10485613</ArticleId><ArticleId IdType="pubmed">37691937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisoschi A.M., Pop A., Iordache F., Stanca L., Geicu O.I., Bilteanu L., Serban A.I. Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy. Eur. J. Med. Chem. 2022;232:114175. doi: 10.1016/j.ejmech.2022.114175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2022.114175</ArticleId><ArticleId IdType="pmc">PMC8813210</ArticleId><ArticleId IdType="pubmed">35151223</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi S.M. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol. Ther. 2021;29:898–900. doi: 10.1016/j.ymthe.2021.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.01.030</ArticleId><ArticleId IdType="pmc">PMC7862013</ArticleId><ArticleId IdType="pubmed">33571463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounis N.G., Koniari I., de Gregorio C., Velissaris D., Petalas K., Brinia A., Assimakopoulos S.F., Gogos C., Kouni S.N., Kounis G.N., et al. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines. 2021;9:221. doi: 10.3390/vaccines9030221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030221</ArticleId><ArticleId IdType="pmc">PMC7999280</ArticleId><ArticleId IdType="pubmed">33807579</ArticleId></ArticleIdList></Reference><Reference><Citation>Risma K.A. COVID-19 mRNA vaccine allergy. Curr. Opin. Pediatr. 2021;33:610–617. doi: 10.1097/MOP.0000000000001077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000001077</ArticleId><ArticleId IdType="pmc">PMC8577302</ArticleId><ArticleId IdType="pubmed">34670264</ArticleId></ArticleIdList></Reference><Reference><Citation>Dézsi L., Mészáros T., Kozma G., H-Velkei M., Oláh C.Z., Patkó Z., Fülöp T., Hennies M., Szebeni M., Barta B.A., et al. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: Complement activation as a possible contributing factor. Geroscience. 2022;44:597–618. doi: 10.1007/s11357-021-00495-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-021-00495-y</ArticleId><ArticleId IdType="pmc">PMC8831099</ArticleId><ArticleId IdType="pubmed">35146583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozma G.T., Meszaros T., Berenyi P., Facsko R., Patko Z., Olah C.Z., Nagy A., Fulop T.G., Glatter K.A., Radovits T., et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing COVID-19 vaccines: Evidence for immunogenicity of PEG. Vaccine. 2023;41:4561–4570. doi: 10.1016/j.vaccine.2023.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.06.009</ArticleId><ArticleId IdType="pmc">PMC10239905</ArticleId><ArticleId IdType="pubmed">37330369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounis N.G. Kounis syndrome: An update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin. Chem. Lab. Med. 2016;54:1545–1559. doi: 10.1515/cclm-2016-0010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2016-0010</ArticleId><ArticleId IdType="pubmed">26966931</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancaccio R., Bonzano L., Cocconcelli A., Boyko R., Ienopoli G., Motolese A. Recurrent Kounis Syndrome: A Case Report and Literature Review. J. Clin. Med. 2024;13:1647. doi: 10.3390/jcm13061647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13061647</ArticleId><ArticleId IdType="pmc">PMC10970901</ArticleId><ArticleId IdType="pubmed">38541873</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda M., Fujimoto W., Yamashita S., Takemoto M., Kuroda K., Imanishi J., Iwasaki M., Todoroki T., Okuda M., Hayashi T. Recurrent cardiac arrests caused by Kounis syndrome without typical allergic symptoms. J. Cardiol. Cases. 2023;27:47–51. doi: 10.1016/j.jccase.2022.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jccase.2022.10.004</ArticleId><ArticleId IdType="pmc">PMC9911913</ArticleId><ArticleId IdType="pubmed">36788958</ArticleId></ArticleIdList></Reference><Reference><Citation>Awaya T., Moroi M., Nakamura F., Toi S., Wakiya M., Enomoto Y., Kunimasa T., Nakamura M. A Possibility of Vasospastic Angina after mRNA COVID-19 Vaccination. Vaccines. 2022;10:1998. doi: 10.3390/vaccines10121998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10121998</ArticleId><ArticleId IdType="pmc">PMC9786293</ArticleId><ArticleId IdType="pubmed">36560408</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.J., Lim J., Bea S., Lee J., Choi J.Y., Rho S.Y., Lee D.I., Na J.O., Kim H.K. Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: A self-controlled case series study. Eur. Heart J. 2024;45:2983–2991. doi: 10.1093/eurheartj/ehae335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae335</ArticleId><ArticleId IdType="pubmed">38993069</ArticleId></ArticleIdList></Reference><Reference><Citation>Aye Y.N., Mai A.S., Zhang A., Lim O.Z.H., Lin N., Ng C.H., Chan M.Y., Yip J., Loh P.H., Chew N.W.S. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. 2021;116:279–283. doi: 10.1093/qjmed/hcab252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab252</ArticleId><ArticleId IdType="pmc">PMC8522388</ArticleId><ArticleId IdType="pubmed">34586408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes R.A., Regateiro F.S., Pita J., Ribeiro C., Carrapatoso I., Todo-Bom A., Faria E. Severe Anaphylaxis with Cardiac Arrest Caused by Prick Test with Cefuroxime. J. Investig. Allergol. Clin. Immunol. 2018;28:426–428. doi: 10.18176/jiaci.0305.</Citation><ArticleIdList><ArticleId IdType="doi">10.18176/jiaci.0305</ArticleId><ArticleId IdType="pubmed">30530392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue T., Inaba S., Sumimoto T., Saito M. Intravascular ultrasound-confirmed plaque rupture following multiple bee stings. Eur. Heart J. 2020;41:1374. doi: 10.1093/eurheartj/ehz789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz789</ArticleId><ArticleId IdType="pubmed">31711149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B.H., Tan H.X., Vijayasingham S. Kounis syndrome following solenopsis (fire ant) bite. Med. J. Malays. 2019;74:344–346.</Citation><ArticleIdList><ArticleId IdType="pubmed">31424048</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipiak K.J., Tarchalska-Krynska B., Opolski G., Rdzanek A., Kochman J., Kosior D.A., Czlonkowski A. Tryptase levels in patients after acute coronary syndromes: The potential new marker of an unstable plaque? Clin. Cardiol. 2003;26:366–372. doi: 10.1002/clc.4950260804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.4950260804</ArticleId><ArticleId IdType="pmc">PMC6654608</ArticleId><ArticleId IdType="pubmed">12918638</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S. Mast cell tryptase level should be checked in all patients with suspected Kounis syndrome. Eur. Heart J. 2020;41:3018. doi: 10.1093/eurheartj/ehaa548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa548</ArticleId><ArticleId IdType="pubmed">32705129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounis N.G. Coronary hypersensitivity disorder: The Kounis syndrome. Clin. Ther. 2013;35:563–571. doi: 10.1016/j.clinthera.2013.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2013.02.022</ArticleId><ArticleId IdType="pubmed">23490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamizadeh S., Brockow K., Ring J. Rupatadine: Efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J. Int. 2014;23:87–95. doi: 10.1007/s40629-014-0011-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40629-014-0011-7</ArticleId><ArticleId IdType="pmc">PMC4479428</ArticleId><ArticleId IdType="pubmed">26120520</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K., Kasama S., Sato M., Kurabayashi M. Myocardial scintigraphic evidence of Kounis syndrome: What is the aetiology of acute coronary syndrome? Eur. Heart J. 2016;37:1157. doi: 10.1093/eurheartj/ehv703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv703</ArticleId><ArticleId IdType="pubmed">26715167</ArticleId></ArticleIdList></Reference><Reference><Citation>Church M.K., Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br. J. Pharmacol. 1987;90:421–429. doi: 10.1111/j.1476-5381.1987.tb08972.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.1987.tb08972.x</ArticleId><ArticleId IdType="pmc">PMC1916952</ArticleId><ArticleId IdType="pubmed">2435353</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushidani S., Kuriyama A. A potential association between myocardial ischemia and epinephrine for anaphylaxis. Am. J. Emerg. Med. 2020;38:1297.e1–1297.e3. doi: 10.1016/j.ajem.2020.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.01.033</ArticleId><ArticleId IdType="pubmed">31983596</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani R., Sekino M., Egashira T., Yano R., Inoue H., Matsumoto S., Higashijima U., Matsumoto S., Yonekura T., Hara T. Allergen-Related Coronary Vasospasm “Kounis Syndrome” Requiring Administration of Epinephrine and a Coronary Vasodilator. J. Cardiothorac. Vasc. Anesth. 2021;35:2768–2771. doi: 10.1053/j.jvca.2020.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.08.009</ArticleId><ArticleId IdType="pubmed">32888803</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan P.Z., Chew N.W.S., Tay S.H., Chang P. The allergic myocardial infarction dilemma: Is it the anaphylaxis or the epinephrine? J. Thromb. Thrombolysis. 2021;52:941–948. doi: 10.1007/s11239-021-02389-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02389-4</ArticleId><ArticleId IdType="pubmed">33544285</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi S., Goto Y., Hirose E., Terashima M., Sakuragi S., Suzuki S., Tsutsumi Y., Miyazaki S., Nonogi H. Successful treatment of refractory vasospastic angina with corticosteroids: Coronary arterial hyperactivity caused by local inflammation? Circ. J. 2004;68:17–22. doi: 10.1253/circj.68.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.68.17</ArticleId><ArticleId IdType="pubmed">14695460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y., Hokimoto S., Harada E., Kinoshita K., Yoshimura M., Yasue H. Variant Aldehyde Dehydrogenase 2 (ALDH2*2) in East Asians Interactively Exacerbates Tobacco Smoking Risk for Coronary Spasm—Possible Role of Reactive Aldehydes. Circ. J. 2016;81:96–102. doi: 10.1253/circj.CJ-16-0969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-16-0969</ArticleId><ArticleId IdType="pubmed">27904031</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnedl W.J., Enko D. Histamine Intolerance Originates in the Gut. Nutrients. 2021;13:1262. doi: 10.3390/nu13041262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13041262</ArticleId><ArticleId IdType="pmc">PMC8069563</ArticleId><ArticleId IdType="pubmed">33921522</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochum C. Histamine Intolerance: Symptoms, Diagnosis, and Beyond. Nutrients. 2024;16:1219. doi: 10.3390/nu16081219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu16081219</ArticleId><ArticleId IdType="pmc">PMC11054089</ArticleId><ArticleId IdType="pubmed">38674909</ArticleId></ArticleIdList></Reference><Reference><Citation>Comas-Baste O., Sanchez-Perez S., Veciana-Nogues M.T., Latorre-Moratalla M., Vidal-Carou M.D.C. Histamine Intolerance: The Current State of the Art. Biomolecules. 2020;10:1181. doi: 10.3390/biom10081181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10081181</ArticleId><ArticleId IdType="pmc">PMC7463562</ArticleId><ArticleId IdType="pubmed">32824107</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar E.L., Hegyesi H., Toth S., Darvas Z., Laszlo V., Szalai C., Falus A. Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. Semin. Cancer Biol. 2000;10:25–28. doi: 10.1006/scbi.2000.0304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/scbi.2000.0304</ArticleId><ArticleId IdType="pubmed">10888268</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimitsu A., Sumigama S., Kotani T., Mano Y., Suzuki K., Araki-Taguchi M., Yamamoto E., Hayakawa H., Okada M., Itakura A., et al. Histamine stimulates interleukin-6 production through histamine H1 receptors in human amnion cells. Gynecol. Obs. Investig. 2010;69:67–72. doi: 10.1159/000257663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000257663</ArticleId><ArticleId IdType="pubmed">19907186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuda Y., Shibamoto T., Yang W., Zhang T., Tanida M., Kurata Y. Blockade of beta2-adrenoceptor, rather than beta1-adrenoceptor, deteriorates cardiac anaphylaxis in isolated blood-perfused rat hearts. Cardiol. J. 2017;24:403–408. doi: 10.5603/CJ.a2017.0034.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2017.0034</ArticleId><ArticleId IdType="pubmed">28353311</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson H.A., Munoz-Furlong A., Campbell R.L., Adkinson N.F., Jr., Bock S.A., Branum A., Brown S.G., Camargo C.A., Jr., Cydulka R., Galli S.J., et al. Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 2006;117:391–397. doi: 10.1016/j.jaci.2005.12.1303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2005.12.1303</ArticleId><ArticleId IdType="pubmed">16461139</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaie S.H., Majidi Zolbanin N., Ahmadi A., Bagherifar R., Valizadeh H., Kashanchi F., Jafari R. Recent advances in mRNA-LNP therapeutics: Immunological and pharmacological aspects. J. Nanobiotechnology. 2022;20:276. doi: 10.1186/s12951-022-01478-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01478-7</ArticleId><ArticleId IdType="pmc">PMC9194786</ArticleId><ArticleId IdType="pubmed">35701851</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams D., Tournev I.L., Taylor M.S., Coelho T., Plante-Bordeneuve V., Berk J.L., Gonzalez-Duarte A., Gillmore J.D., Low S.C., Sekijima Y., et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. Amyloid. 2023;30:18–26. doi: 10.1080/13506129.2022.2091985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506129.2022.2091985</ArticleId><ArticleId IdType="pubmed">35875890</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi S., Matsui-Masai M., Yasui F., Hayashi A., Tockary T.A., Mochida Y., Akinaga S., Kohara M., Kataoka K., Uchida S. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol. Ther. 2024;32:1266–1283. doi: 10.1016/j.ymthe.2024.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2024.03.022</ArticleId><ArticleId IdType="pmc">PMC11081875</ArticleId><ArticleId IdType="pubmed">38569556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho N.T., Hughes S.G., Ta V.T., Phan L.T., Do Q., Nguyen T.V., Pham A.T.V., Thi Ngoc Dang M., Nguyen L.V., Trinh Q.V., et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: Pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat. Commun. 2024;15:4081. doi: 10.1038/s41467-024-47905-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47905-1</ArticleId><ArticleId IdType="pmc">PMC11094049</ArticleId><ArticleId IdType="pubmed">38744844</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Pilipich N., Beloki U., Salaberry L., Smerdou C. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Vaccines. 2024;12:318. doi: 10.3390/vaccines12030318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030318</ArticleId><ArticleId IdType="pmc">PMC10974399</ArticleId><ArticleId IdType="pubmed">38543952</ArticleId></ArticleIdList></Reference><Reference><Citation>Saputra P.B.T., Kurniawan R.B., Trilistyoati D., Farabi M.J.A., Susilo H., Alsagaff M.Y., Oktaviono Y.H., Sutanto H., Gusnanto A., Dyah Kencono Wungu C. Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases. Biomol. Biomed. 2023;23:546–567. doi: 10.17305/bb.2022.8779.</Citation><ArticleIdList><ArticleId IdType="doi">10.17305/bb.2022.8779</ArticleId><ArticleId IdType="pmc">PMC10351100</ArticleId><ArticleId IdType="pubmed">36803547</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  CDC Vaccines &amp; Immunizations. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States.  [(accessed on 24 July 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>